Patent application number | Description | Published |
20080317805 | LOCALLY ADMINISTRATED LOW DOSES OF CORTICOSTEROIDS - This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot. | 12-25-2008 |
20090263444 | Fluocinolone Formulations in a Biodegradable Polymer Carrier - Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or treat sciatic pain and/or inflammation. In various embodiments, prevent transplant rejection for at least twenty-five days. In some embodiments, the pain relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 10-22-2009 |
20090263450 | ALPHA ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OF INFLAMMATORY DISEASES - Effective treatments of pain and/or inflammation from tendonitis, carpal tunnel syndrome, tarsal tunnel syndrome, osteoarthritis, bursitis and/or an oral-facial disease are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation from tendonitis, carpal tunnel syndrome, tarsal tunnel syndrome, osteoarthritis, bursitis and/or an oral-facial disease. | 10-22-2009 |
20090263463 | ALPHA ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OF PAIN AND/OR INFLAMMATION - Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation. | 10-22-2009 |
20090264477 | BETA ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OF PAIN AND/OR INFLAMMATION - Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least one beta adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation. | 10-22-2009 |
20090264489 | Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation - Effective methods for treating pain are provided. Through the injection of liquid formulation comprising an active ingredient followed by the administration of drug depot comprising an active ingredient at or near a target site, one can effectively treat pain. This methodology is particularly effective to treat acute radicular pain. | 10-22-2009 |
20090264490 | CLONIDINE FORMULATIONS IN A BIODEGRADABLE POLYMER CARRIER - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 10-22-2009 |
20100114075 | DEVICE AND METHOD FOR DIRECTIONAL DELIVERY OF A DRUG DEPOT - Drug depot delivery devices and methods are provided for delivering one or more drug depots to one or more sites beneath the skin of a patient with or without repositioning the cannula. The device has a cannula capable of insertion to the site beneath the skin of the patient and one or more side port openings for delivering a drug depot. The side port openings are spaced a distance from the blunt tip, which will allow the user to implant at a set distance from a nerve. The device may also include an electronic monitor for detecting the proximity of the tip of the cannula to a nerve. In some embodiments, a method of delivering a drug depot is provided by detecting the nerve and delivering the drug depot at or near the nerve. | 05-06-2010 |
20120142643 | CLONIDINE AND GABA COMPOUNDS IN A BIODEGRADABLE POLYMER CARRIER - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine and a gamma-aminobutyric acid compound at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 06-07-2012 |
20120142648 | METHODS FOR DELIVERING CLONIDINE COMPOSITIONS IN BIODEGRADABLE POLYMER CARRIER AND LOCAL STERIODS TO A TARGET TISSUE SITE - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine and a steroid at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 06-07-2012 |
20120142649 | COMPOSITIONS AND METHODS FOR DELIVERING CLONIDINE AND BUPIVACAINE TO A TARGET TISSUE SITE - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of immediate release bupivacaine or lidocaine and a sustained release clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days or longer. | 06-07-2012 |
20120142747 | COMPOSITIONS AND METHODS FOR DELIVERING CLONIDINE TO A TARGET TISSUE SITE - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of immediate release clonidine and a sustained release clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days or longer. | 06-07-2012 |
20140336162 | LOCALLY ADMINISTRATED LOW DOSES OF CORTICOSTEROIDS - This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot. | 11-13-2014 |